Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Burris Discusses Targeting the mTOR Pathway

January 31st 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Fox Discusses Genomic Testing in Breast Cancer

January 27th 2012

Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer

Dr. Burstein on Pathological Complete Response

January 20th 2012

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

Dr. Vahdat Discusses the Side Effects of Halaven

January 18th 2012

Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven

HER2-Positive Patients Benefit From Combination Therapy of Trastuzumab and Lapatinib

January 17th 2012

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.

Dr. Perez Discusses Obesity as a Predictive Marker

January 16th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Obesity as a Predictive Marker

PARP Inhibition Explored in Triple-Negative Breast Cancer

January 16th 2012

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Tripathy on the Miami Breast Cancer Conference

January 12th 2012

Dr. Debu Tripathy, from USC Norris Comprehensive Cancer Center, on the Miami Breast Cancer Conference

NKTR 102 Will Move to a Phase III Trial in Pretreated Metastatic Breast Cancer

January 11th 2012

A phase II study of NKTR 102 suggest that this agent will find a role in the treatment of patients with heavily pretreated metastatic breast cancer whose disease is progressing.

Dr. Hudis Discusses Axillary Lymph Node Status

January 10th 2012

Dr. Clifford Hudis, from Memorial Sloan-Kettering Cancer Center, Discusses Axillary Lymph Node Status

Breast Cancer Treatment Update

January 6th 2012

Beth Baughman DuPree, MD, FACS, discussed the latest in breast cancer care at the 3rd Annual NCONN Conference.

Overcoming Resistance to Endocrine Therapies

December 29th 2011

Patients with hormone receptor-positive metastatic breast cancer (MBC) frequently respond to multiple lines of endocrine therapy but, unfortunately, resistance eventually develops.

Keeping Patients in Mind: Noted Breast Cancer Researcher Pursues Broad Notion of Personalized Medicine

December 28th 2011

One of a small group of scientists who had a hand in developing Herceptin (trastuzumab) for the treatment of breast cancer, Dr. Debu Tripathy's current work is focused on understanding why some patients are resistant to the drug, and how to create more effective therapies for them.

Exploiting Oncogene Addiction and Immunogenicity May Be Path to Improved Results in HER2-Positive Breast Cancer

December 27th 2011

The approval of trastuzumab, targeted directly to the human epidermal growth factor receptor (HER2)-positive, was a major advance in extending the lives of women with HER2-positive breast cancer.

Dr. Vahdat Compares Halaven and Ixempra Neuropathy

December 22nd 2011

Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy

Dr. Perez Discusses the B-34 Clodronate Study

December 22nd 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Florida, Discusses the B-34 Clodronate Study

Pharmacogenomics in Action: CYP2D6 Breast Cancer Debate Shows Intricacies of Genotyping

December 21st 2011

Recently reported and truly impressive clinical trial data have revealed the relevance of administering antineoplastic agents specifically and prospectively targeted to molecular abnormalities.

Adjuvant Zoledronic Acid May Improve Disease-Free Survival for Postmenopausal Women With Breast Cancer

December 15th 2011

A subanalysis of the AZURE study found that postmenopausal women had a disease-free survival advantage from the addition of zoledronic acid to their therapy.

Dr. Baselga Describes the Advantages of Dual Blockade

December 14th 2011

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Dr. Perez Discusses the BOLERO-2 Everolimus Trial

December 14th 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses the BOLERO-2 Everolimus Trial